Acquisitions expanding footprint Strategic acquisitions of Affinity Biologicals and George King Bio-Medical broaden Precision BioLogic’s product portfolio and customer base in hemostasis diagnostics, creating cross-sell opportunities for antibodies, coagulation-related reagents, and specialty plasmas to existing labs and new regional markets.

CRYOcheck product family Strong emphasis on CRYOcheck line of frozen plasmas, chromogenic assays, and specialized test kits positions the company to upsell across laboratories seeking comprehensive hemostasis solutions, including Factor VIII and IX testing with recent chromogenic expansions.

Regulatory and market expansion Global rollout milestones in Canada, EU, UK, Australia, and New Zealand suggest readiness for further international distribution partnerships and regulatory-enabled sales, offering channels to push new assays and diagnostic products through established networks.

Clinical lab reach Serving over 1,000 clinical laboratories with overnight direct delivery indicates a ready-to-activate demand channel for launches of new reagents, controls, and assay kits, with potential for regional account targeting and faster adoption.

Growth through partnerships Recent financing and partnership activity, including Procuritas involvement, signals a growth-oriented strategy that can be leveraged to pursue co-development, co-marketing, and strategic distribution deals to accelerate market penetration and product diversification.